NICE rules on further indications for golimumab and abatacept

Golimumab can also be prescribed on the NHS to treat RA after the failure of conventional DMARDs | SCIENCE PHOTO LIBRARY
Golimumab can also be prescribed on the NHS to treat RA after the failure of conventional DMARDs | SCIENCE PHOTO LIBRARY

NICE has published technology appraisals for two biologics used in the treatment of musculoskeletal inflammatory disease.

Golimumab (Simponi) is now recommended as an option for the treatment of severe, active ankylosing spondylitis (AS) in adults with all of the following:

  • Disease that satisfies the modified New York criteria for diagnosis of AS
  • Confirmation of sustained active spinal disease on two occasions at least 12 weeks apart without any change in treatment (score of at least 4 units on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and at least 4cm on the spinal pain Visual Analogue Scale (VAS)
  • Treatment with two or more NSAIDs taken sequentially for 4 weeks has failed.

The manufacturer must provide the 100mg dose of golimumab, needed in people who weigh more than 100kg, at the same cost as the 50mg dose.

Treatment response should be assessed every 12 weeks. If an adequate response (defined as a reduction of BASDAI to 50% of the pre-treatment value or by at least 2 units, and a reduction in VAS by 2cm or more) is not maintained, the response should be reassessed after a further six weeks and discontinued if it remains inadequate.

Abatacept (Orencia), in combination with methotrexate, is not recommended for the treatment of moderate to severe active rheumatoid arthritis when one or more conventional DMARDs, including methotrexate, has failed.

NICE – golimumab in AS

NICE – abatacept in RA (second-line)

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases